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Background: Alzheimer’s disease (AD) is a neurologically degenerative disorder that affects more than 20 million
people worldwide. The selective butyrylcholinesterase (BChE) inhibitors and bivalent cholinesterase (ChE) inhibitors
represent new treatments for AD.
Findings: A series of lycorine derivatives (1–10) were synthesized and evaluated for anti-cholinesterase activity.
Result showed that the novel compound 2-O-tert-butyldimethylsilyl-1-O-(methylthio)methyllycorine (7) was a dual
inhibitor of human acetylcholinesterase (hAChE) and butyrylcholinesterase (hBChE) with IC50 values of 11.40 ± 0.66 μM
and 4.17 ± 0.29 μM, respectively. The structure-activity relationships indicated that (i) the 1-O-(methylthio)methyl
substituent in lycorine was better than the 1-O-acetyl group for the inhibition of cholinesterase; (ii) the acylated or
etherified derivatives of lycorine and lycorin-2-one were more potent against hBChE than hAChE; and (iii) the oxidation
of lycorine at C-2 decreases the activity.
Conclusion: Acylated or etherified derivatives of lycorine are potential dual inhibitors of hBChE and hAChE. Hence,
further study on the modification of lycorine for ChE inhibition is necessary.
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Alzheimer’s disease (AD) is a neurologically degenerative
disorder that affects more than 20 million people world-
wide [1], and is the third-most costly disease after
cardiovascular disease and cancer [2]. The neuropatho-
logical hallmarks of the disease include β-amyloid (Aβ)
plaques, neurofibrillary tangles, and synaptic loss. Based
on the cholinergic hypothesis, the symptoms of AD are
the result of the reduction in brain acetylcholine (ACh)
activity due to the catabolism of ACh by its principal
hydrolytic enzyme acetylcholinesterase (AChE). AChE
inhibition is the current approach for AD treatment.
Tacrine, donepezil, rivastigmine, and galanthamine are
all examples of typical AChE inhibitory drugs [3].* Correspondence: wangyuehu@mail.kib.ac.cn; chunlinlong@hotmail.com
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reproduction in any medium, provided the orSimilar to AChE, butyrylcholinesterase (BChE) can also
inactivate ACh. The reduction in ACh is usually accom-
panied by a decrease in AChE activity. By contrast, BChE
in AD remains at normal levels or even elevated in the
brain. BChE may be a significant contributor to the
observed loss of ACh in AD [4]. Furthermore, BChE
inhibition can lower Aβ peptide [5,6]. BChE is essential in
AD plaque maturation [7]. Selective BChE inhibition may
be crucial in the mid to late stages of AD pathogenesis to
circumvent further decline in mental and cognitive ability
as the depletion of cholinergic neurons persists [3]. Hence,
selective BChE inhibitors or bivalent ChE inhibitors repre-
sent a new treatment for AD.
Lycorine, the most frequent alkaloid in Amaryllidaceae
plants, has very weak inhibitory activity against electric
eel acetylcholinesterase (eeAChE), with an IC50 value of
213 μM [8]. Acylated or etherified derivatives of lycorine,
such,as 1-O-acetyllycorine and 1-O-acetyl-2-O-tert-butyldi-
methylsilyllycorine (6, Figure 1), possess potent activity
against eeAChE [8,9]. However, the inhibitory effect of ana-
logues on BChE has not been reported. In our continuingl Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Chemical structures of compounds under study.
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http://journal.chemistrycentral.com/content/6/1/96work on Amaryllidaceae alkaloids [10-12], the present
study reports the synthesis of lycorine derivatives (1–10),
and their biological evaluation for inhibition of ChE.
Previous researchers considered that a hydrogen-bond
acceptor at the C-1 of lycorine is necessary for AChE
inhibitory activity, and a bulky, lipophilic substituent,
such as the TBS group, at C-2 increases the activity
[9,13]. Therefore, in the present study, benzoic acid or
cinnamic acid were used to acylate the 1-OH and/or
2-OH of lycorine and its C-1 or C-2 oxidation deriva-
tives. Mono- or di-acylated derivatives (1–5, and 10) of
lycorine and lycorin-2-one (8) were obtained by Steglich
esterification (DCC/DMAP). Lycorine oxidation using
pyridinium chlorochromate (PCC) in DMF yielded 8,
and the acetylated analogue (9) of the latter was
obtained by the reaction of 8 with Ac2O/pyridine. The
DMSO/Ac2O system was used to oxidate C-1 of lycor-
ine, with the protection of 1-OH by the TBS group.
However, 1-O-acetyl and 1-O-(methylthio)methyl deriva-
tives (6 and 7) were obtained instead of the desired C-1
oxidation product.
The anti-ChE activity of these prepared lycorine deriva-













Galanthamine (positive control)modified from Ellman’s method [14]. The results were
expressed as IC50 values and summarized in Table 1.
2-O-tert-Butyldimethylsilyl-1-O-(methylthio)methylly-
corine (7) showed dual inhibitory activity against both
hAChE (IC50 = 11.40 ± 0.66 μM) and hBChE (IC50 =
4.17 ± 0.29 μM). The inhibitory potency of 7 was
approximately four-fold stronger than that of galantha-
mine (IC50 = 18.30 ± 0.14 μM) on hBChE. Compounds
1, and 2−4 also showed good effects on hBChE, with
IC50 values of less than 20 μM.
Table 1 shows that the acylated or etherified deriva-
tives (1, 3–5, 7, 9, and 10) of lycorine and lycorin-2-one
are more potent against hBChE than hAChE. The
hBChE inhibitory activity of 1-O-trans-cinnamoyllycorine
(5, IC50 = 12.13 ± 0.77 μM) is about two-fold better than
that of 1-O-trans-cinnamoyllycorin-2-one (10, IC50 =
20.91 ± 0.13 μM). This result implied that lycorine oxida-
tion at C-2 may decrease the activity.
A previous study reported that 1-O-acetyl-2-O-tert-
butyldimethylsilyllycorine (6) showed significant in-
hibitory activity against ACh biotransformation by
eeAChE (Ki = 0.34 μM) [9]. However, in the current




1 > 50 7.72 ± 0.26
2 > 50 > 50
3 46.76 ± 0.95 17.45 ± 0.19
4 > 50 19.74 ± 1.37
5 > 50 12.13 ± 0.77
6 > 50 > 50
7 11.40 ± 0.66 4.17 ± 0.29
8 > 50 > 50
9 > 50 44.46 ± 0.88
10 > 50 20.91 ± 0.13
0.26 ± 0.015 0.02 ± 0.00
1.60 ± 0.14 18.30 ± 0.14
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http://journal.chemistrycentral.com/content/6/1/96inactive (IC50 > 50 μM) against both of hAChE and
hBChE. 1-O-(Methylthio)methyl substituent at C-1 of
lycorine significantly increased the inhibitory activity
against both of hAChE and hBChE in 7 compared with
that of 6. Compound 7 was an unexpected product; its
formation mechanism can be explained by a Pummerer
rearrangement (Scheme 1) [15].
The bioassay result of compound 7 compared with
those of other tested compounds showed that a bulky,
lipophilic substituent at C-1 or C-2 of lycorine is
necessary for the human ChE inhibitory activity. In
addition, the substituted group at C-1 is important in
the activity.
The positive control tacrine showed a significant
inhibitory effect on both hAChE and hBChE. How-
ever, tacrine is currently rarely used because of its
hepatotoxicity [16]. Based on the results in the
present study, modification of lycorine for the inhib-
ition of ChE, especially of hBChE, is necessary.Experimental
Chemistry
NMR spectra were recorded on Bruker AM-400 and
DRX-500 spectrometers with TMS as an internal
standard. ESIMS data were measured on an API-
Qstar-Pulsar-1 instrument and HREIMS on a Waters
Autospec Premier P776 mass spectrometer. Column
chromatography was performed over silica gel G (80–100
and 300–400 mesh), silica gel H (10–40 μm), and Sepha-
dex LH-20 (40–70 μm; Amersham Pharmacia Biotech
AB). TLC was conducted on precoated silica gel plates
GF254. HPLC separations were performed using an Agi-
lent 1200 series pump equipped with a diode array de-
tector, a semi-preparative Agilent Zorbax SB-C18 (5 μm,
9.4 × 250 mm) column, and a semi-preparative Waters




Scheme 1 The proposed mechanism for the formation of 7.Preparation of the acylated derivatives (1–5 and 10) of
lycorine and lycorin-2-one
A suspension of lycorine or lycorin-2-one (1 mmol),
cinnamic acid or benzoic acid (1 eq.), dicyclohexylcar-
bodiimide (1 eq.), and 4-(N,N-dimethylamino)pyridine
(1 eq.) in 25 mL of dry DMF was stirred for 12 h at
room temperature. The urea byproduct was filtered,
and the filtrate was evaporated. The resulting residue
was purified by column chromatography on silica gel,
using a mixture of hexane-CHCl3-Me2CO (10:2:1),
CHCl3, and CHCl3-MeOH (100:1) as eluent to yield
the products (1–5 and 10).
1,2-O,O'-Dibenzoyllycorine (1)
Elution with hexane-CHCl3-Me2CO (10:2:1) and CHCl3
afforded 1[17] as a colorless solid, with a yield of 2.5%;
1H-NMR (CDCl3, 400 MHz): δ 8.06 (d, J = 7.7 Hz, 2H,
H-2'',6''), 7.91 (d, J = 7.7 Hz, 2H, H-2',6'), 7.55 (m, 2H,
H-4',4''), 7.42 (m, 4H, H-3',5',3'',5''), 6.84 (s, 1H, H-8),
6.59 (s, 1H, H-12), 6.16 (br s, 1H, H-1), 5.90 and 5.86
(s, 1H each, H2-11), 5.69 (br s, 2H, H-2,3), 4.09 and 3.62
(br s, 1H each, H2-7), 3.47 and 2.53 (m, 1H each, H2-5),
3.19 (m, 1H, H-12c), 3.06 (m, 1H, H-12b), 2.77 (m, 2H,
H2-4); ESIMS m/z: 496 [M + H]
+; HREIMS for
C30H25NO6 [M]
+: calcd. 495.1682; found: 495.1682.
2-O-Benzoyllycorine (2)
Elution with CHCl3-MeOH (100:1) afforded 2 [17] as a
colorless solid, with a yield of 12.0%; 1H-NMR (CDCl3,
400 MHz): 1H-NMR (CDCl3, 400 MHz): δ 8.02
(d, J = 7.3 Hz, 2H, H-2',6'), 7.54 (t, J = 7.3 Hz, 1H, H-4'),
7.40 (t, J = 7.3 Hz, 2H, H-3',5'), 6.80 (s, 1H, H-8), 6.58 (s,
1H, H-12), 5.87 and 5.87 (s, 1H each, H2-11), 5.58 (br s,
2H, H-2,3), 4.64 (br s, 1H, H-1), 4.16 and 3.55 (d, J =
14.2 Hz, 1H each, H2-7), 3.37 and 2.40 (m, 1H each,
H2-5), 2.89 (d, J = 10.5 Hz, 1H, H-12b), 2.83 (d, J = 10.5
Hz, 1H, H-12c), 2.67 (m, 2H, H2-4);
13C-NMR (CDCl3,
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http://journal.chemistrycentral.com/content/6/1/96(C-3a,9), 133.1 (C-4'), 130.0 and 129.8 (C-7a,1'), 129.7 ×
2 (C-2',6'), 128.3 × 2 (C-3',5'), 127.3 (C-12a), 113.7 (C-3),
107.5 (C-8), 104.8 (C-12), 100.9 (C-11), 74.1 (C-1), 69.0
(C-2), 60.7 (C-12c), 57.0 (C-7), 53.7 (C-5), 41.8 (C-12b),
28.7 (C-4); ESIMS m/z: 392 [M + H]+; HREIMS for
C23H21NO5 [M]
+: calcd. 391.1420; found: 391.1413.
1,2-O,O'-Di-trans-cinnamoyllycorine (3)
Elution with hexane-CHCl3-Me2CO (10:2:1) and CHCl3
afforded 3 as a colorless solid, with a yield of 3.5%;
1H-NMR (CDCl3, 400 MHz): δ 7.71 (d, J = 16.1 Hz,
1H, H-7''), 7.64 (d, J = 16.1 Hz, 1H, H-7'), 7.52 (m,
2H, H-2'',6''), 7.46 (m, 2H, H-2',6'), 7.38 (m, 3H, H-
3'',4'',5''), 7.34 (m, 3H, H-3',4',5'), 6.84 (s, 1H, H-8),
6.60 (s, 1H, H-12), 6.45 (d, J = 16.1 Hz, 1H, H-8''),
6.32 (d, J = 16.1 Hz, 1H, H-8'), 5.99 (br s, 1H, H-1),
5.90 and 5.88 (s, 1H each, H2-11), 5.65 (br s, 1H,
H-2), 5.51 (br s, 1H, H-3), 4.18 and 3.62 (d, J = 11.4
Hz, 1H each, H2-7), 3.40 and 2.50 (m, 1H each,
H2-5), 3.06 (d, J = 9.6 Hz, 1H, H-12c), 2.97 (m, 1H,
H-12b), 2.73 (m, 2H, H2-4);
13C-NMR (CDCl3, 100
MHz): δ 165.8 and 165.5 (C-9',9''), 146.4 (C-10),
145.8 and 145.5 × 3 (C-3a,9,7',7''), 134.3 and 134.1
(C-1',1''), 130.4 and 130.4 (C-7a,12a), 128.9 × 2 and
128.8× 2 (C-3',5',3'',5''), 128.1 × 4 (C-2',6',2'',6''),
126.6 × 2 (C-4',4''), 117.7 and 117.3 (C-8',8''), 114.3
(C-3), 107.4 (C-8), 105.2 (C-12), 101.0 (C-11), 70.7
(C-1), 69.1 (C-2), 61.3 (C-12c), 56.7 (C-7), 53.7 (C-5),
40.4 (C-12b), 28.8 (C-4); ESIMS m/z: 548 [M + H]+;




Elution with CHCl3-MeOH (100:1) afforded 4 as a color-
less solid, with a yield of 16.7%; 1H-NMR (CDCl3, 400
MHz): δ 7.70 (d, J = 16.1 Hz, 1H, H-7'), 7.50 (m, 2H,
H-2',6'), 7.38 (m, 3H, H-3',4',5'), 6.84 (s, 1H, H-8), 6.61
(s, 1H, H-12), 6.43 (d, J = 16.1 Hz, 1H, H-8'), 5.91 and
5.90 (s, 1H each, H2-11), 5.57 (br s, 1H, H-2), 5.48 (br s,
1H, H-3), 4.62 (br s, 1H, H-1), 4.14 and 3.68 (d, J = 14.1
Hz, 1H each, H2-7), 3.38 and 2.59 (m, 1H each, H2-5),
3.01 (m, 1H, H-12b), 2.82 (d, J = 8.7 Hz, 1H, H-12c),
2.71 (m, 2H, H2-4);
13C-NMR (CDCl3, 100 MHz):
δ 166.3 (C-9'), 146.4 (C-10), 145.5 × 3 (C-3a,9,7'), 134.2
(C-1'), 130.4 × 2 (C-7a,12a), 128.9 × 2 (C-3',5'), 128.1 × 2
(C-2',6'), 127.3 (C-4'), 117.7 (C-8'), 113.8 (C-3), 107.6
(C-8), 104.8 (C-12), 101.0 (C-11), 73.5 (C-1), 68.9 (C-2),
60.5 (C-12c), 56.5 (C-7), 53.8 (C-5), 41.3 (C-12b), 28.9
(C-4); ESIMS m/z: 418 [M + H]+; HREIMS for
C25H23NO5 [M]
+: calcd. 417.1576; found: 417.1567.
1-O-trans-Cinnamoyllycorine (5)
Elution with CHCl3-MeOH (50:1) afforded 5 as a color-
less solid, with a yield of 1.4%; 1H-NMR (CDCl3, 400MHz): 1H-NMR (CDCl3, 400 MHz): δ 7.59 (d, J = 16.0
Hz, 1H, H-7'), 7.45 (m, 2H, H-2',6'), 7.33 (m, 3H,
H-3',4',5'), 6.64 (s, 1H, H-8), 6.59 (s, 1H, H-12), 6.28 (d,
J = 16.0 Hz, 1H, H-8'), 5.89 and 5.87 (s, 1H each,
H2-11), 5.72 (br s, 1H, H-1), 5.59 (br s, 1H, H-3), 4.27
(br s, 1H, H-2), 4.19 and 3.61 (d, J = 14.0 Hz, 1H each,
H2-7), 3.37 and 2.51 (m, 1H each, H2-5), 2.95 (m, 2H,
H-12b,12c), 2.67 (m, 2H, H2-4);
13C-NMR (CDCl3, 100
MHz): δ 166.6 (C-9'), 146.6 (C-10), 146.3 and 145.5 × 2
(C-3a,9,7'), 134.1 (C-1'), 130.4 × 2 (C-7a,12a), 128.8 × 2
(C-3',5'), 128.1 × 2 (C-2',6''), 127.1 (C-4'), 117.5 (C-8'),
113.8 (C-3), 107.4 (C-8), 104.9 (C-12), 100.9 (C-11), 72.6
(C-1), 69.4 (C-2), 61.5 (C-12c), 56.8 (C-7), 53.7 (C-5),
39.1 (C-12b), 28.7 (C-4); ESIMS m/z: 418 [M + H]+;
HREIMS for C25H23NO5 [M]
+: calcd. 417.1576; found:
417.1583.1-O-trans-Cinnamoyllycorin-2-one (10)
Elution with hexane-CHCl3-Me2CO (10:2:1), CHCl3, and
CHCl3-MeOH (100:1) afforded 10 as a colorless solid,
with a yield of 62.7%; 1H-NMR (CDCl3, 400 MHz):
δ 7.63 (d, J = 16.0 Hz, 1H, H-7'), 7.44 (m, 2H, H-2',6'),
7.34 (m, 3H, H-3',4',5'), 6.79 (s, 1H, H-8), 6.57 (s, 1H, H-
12), 6.28 (d, J = 16.0 Hz, 1H, H-8'), 6.14 (d, J = 1.6 Hz,
1H, H-1), 6.03 (br s, 1H, H-3), 5.90 and 5.89 (s, 1H each,
H2-11), 4.18 and 3.65 (d, J = 14.0 Hz, 1H each, H2-7),
3.48 and 2.59 (m, 1H each, H2-5), 3.35 (m, 2H, H-
12b,12c), 2.90 (m, 2H, H2-4);
13C-NMR (CDCl3, 100
MHz): δ 204.4 (C-2), 165.5 (C-9'), 146.7 × 2 (C-3a,10),
146.1 × 2 (C-9,7'), 134.1 (C-1'), 130.5 × 2 (C-7a,12a),
128.8 × 2 (C-3',5'), 128.1 × 2 (C-2',6''), 125.2 (C-4'), 120.6
(C-3), 116.9 (C-8'), 107.3 (C-8), 105.4 (C-12), 101.1
(C-11), 68.9 (C-1), 62.3 (C-12c), 56.1 (C-7), 53.2 (C-5), 45.4
(C-12b), 30.0 (C-4); ESIMS m/z: 416 [M + H]+; HREIMS
for C25H21NO5 [M]
+: calcd. 415.1420; found: 415.1418.Synthesis of 1-O-acetyl-2-O-tert-butyldimethylsilyllycorine
(6) and 2-O-tert-butyldimethylsilyl-1-O-(methylthio)
methyllycorine (7)
A solution of 2-O-tert-butyldimethylsilyllycorine [9] (60
mg, 0.150 mmol), dry dimethyl sulfoxide (0.26 mL), and
acetic anhydride (0.18 mL) was stirred overnight at room
temperature. Afterward, the reaction mixture was
quenched with H2O (0.7 mL) and aqueous NH4OH
(0.4 mL). The resulting solution was extracted with
Et2O. The organic layer was separated, dried over
Na2SO4, and then concentrated. The residue was purified
by silica gel column chromatography (petrol/EtOAc, 10:1)
and HPLC with a Waters XBridge C-18 column (5 μm,
10 × 250 mm) using MeOH-H2O (95:5) as eluent to yield
6 [9] (tR = 9.876 min, 23 mg, 0.0530 mmol) and 7 (tR =
11.955 min, 17 mg, 0.0368 mmol).
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A white solid, yield 35.4%; 1H-NMR (CDCl3, 400 MHz):
δ 6.73 (s, 1H, H-8), 6.56 (s, 1H, H-12), 5.92 and 5.91 (s,
1H each, H2-11), 5.55 (br s, 1H, H-1), 5.39 (br s, 1H,
H-3), 4.17 (br s, 1H, H-2), 4.14 and 3.52 (d, J = 14.1 Hz,
1H each, H2-7), 3.36 and 2.37 (m, 1H each, H2-5), 2.94
(d, J = 8.8 Hz, 1H, H-12b), 2.74 (d, J = 8.8 Hz, 1H,
H-12c), 2.63 (m, 2H, H2-4), 1.94 (s, 3H, O(CO)CH3),
0.89 (s, 9H, SiC(CH3)3), 0.19 and 0.11 (s, 3H each, Si
(CH3)2); ESIMS m/z: 444 [M + H]
+; HREIMS for
C24H33NO5Si [M]
+: calcd. 443.2128; found: 443.2127.
2-O-tert-Butyldimethylsilyl-1-O-(methylthio)methyllycorine (7)
A pale yellow solid, yield 24.5%; 1H-NMR (CDCl3,
400 MHz): δ 7.02 (s, 1H, H-8), 6.56 (s, 1H, H-12),
5.91 and 5.91 (s, 1H each, H2-11), 5.42 (br s, 1H,
H-3), 4.66 and 4.62 (d, J = 12.0 Hz, 1H each,
OCH2SCH3), 4.51 (br s, 1H, H-1), 4.34 (br s, 1H,
H-2), 4.12 and 3.50 (d, J = 14.0 Hz, 1H each, H2-7),
3.34 and 2.33 (m, 1H each, H2-5), 2.88 (d, J = 10.4
Hz, 1H, H-12b), 2.73 (d, J = 10.4 Hz, 1H, H-12c),
2.61 (m, 2H, H2-4), 1.97 (s, 3H, SCH3), 0.89 (s, 9H,
SiC(CH3)3), 0.16 and 0.12 (s, 3H each, Si(CH3)2);
ESIMS m/z: 462 [M + H]+; HREIMS for C24H35NO4-
SiS [M]+: calcd. 461.2056; found: 461.2058.
Lycorin-2-one (8)
Lycorine [10,12] (1 g, 3.481 mmol), PCC (6.657 g,
30.886 mmol) and silica gel (6.657 g) in anhydrous DMF
(50 mL) were stirred at room temperature for 24 h.
Afterward, the reaction mixture was filtrated through a
pad of Celite. The filtrate was then poured into water,
adjusted the pH to 9 using ammonia, and extracted with
CHCl3. The solvent was evaporated under reduced pres-
sure. The residue was purified by silica gel column chro-
matography (CHCl3-MeOH, 20:1) to yield 8 [18,19] (70
mg, 0.245 mmol).
A gray powder, yield 7.0%; 1H-NMR (CDCl3, 500
MHz): δ 6.77 (s, 1H, H-8), 6.60 (s, 1H, H-12), 5.97 and
5.95 (s, 1H each, H2-11), 5.93 (br s, 1H, H-3), 4.55 (d,
J = 2.3 Hz, 1H, H-1), 4.16 and 3.64 (d, J = 14.0 Hz, 1H
each, H2-7), 3.45 and 2.53 (m, 1H each, H2-5), 3.25 (br s,
1H, H-12b), 3.14 (d, J = 9.4 Hz, 1H, H-12c), 2.86 (br s,
2H, H2-4); ESIMS m/z: 286 [M + H]
+; HREIMS for
C16H15NO4 [M]
+: calcd. 285.1001; found: 285.1000.
1-O-Acetyllycorin-2-one (9)
A suspension of (20 mg, 0.0702 mmol) of lycorin-2-one
(8) in 0.5 mL of pyridine and 0.5 mL Ac2O was stirred
for 12 h at room temperature and then 20 mL of water
was added. The solution was adjusted to pH 9 using
ammonia (5 mL) and extracted with CHCl3 for four
times before the removal of CHCl3. The resultingresidue was purified by prep. TLC (CHCl3-MeOH, 30:1)
to yield 9 (5 mg, 0.0153 mmol).
A gray solid, yield 21.8%; 1H-NMR (CDCl3, 400
MHz): δ 6.72 (s, 1H, H-8), 6.57 (s, 1H, H-12), 6.00
and 5.99 (s, 1H each, H2-11), 5.93 and 5.92 (br s, 1H
each, H-1,3), 4.17 and 3.61 (d, J = 14.1 Hz, 1H each,
H2-7), 3.48 and 2.52 (m, 1H each, H2-5), 3.26 (br d,
J = 10.0 Hz, 1H, H-12b), 3.16 (d, J = 10.0 Hz, 1H, H-12c),
2.86 (m, 2H, H2-4), 1.96 (s, 3H, O(CO)CH3); ESIMS
m/z: 328 [M + H]+; HREIMS for C18H17NO5 [M]
+:
calcd. 327.1107; found: 327.1105. The NMR spectra
of compounds 1–10 were also available as a PDF file
(Additional file 1).Cholinesterase inhibitory activity
AChE/BChE inhibitory activity of compounds 1–10
(purity >95%) was assayed using the spectrophotomet-
ric method developed by Ellman et al. [14], with slight
modification. S-Acetylthiocholine iodide, S-butyrylthio-
choline iodide, 5,5'-dithio-bis-(2-nitrobenzoic) acid (DTNB,
Ellman’s reagent), hAChE, and hBChE, were pur-
chased from Sigma Chemical. The test compounds
were dissolved in DMSO. The reaction mixture con-
tained 110 μL of phosphate buffer (pH 8.0), 10 μL of
test compounds (50 μM), and 40 μL of hAChE or
hBChE (0.04 U/100 μL), and the mixture was incu-
bated for 20 min (30 °C). Subsequently, the reaction
was initiated by the addition of 20 μL of DTNB (6.25
mM) and 20 μL of ACh or butyrylthiocholine (BCh)
for hAChE or hBChE inhibitory activity, respectively.
Hydrolysis of ACh or BCh was monitored at 405 nm
after 30 min. All reactions were performed in tripli-
cate. Inhibition percentage was calculated as follows:
% inhibition = (E − S)/E × 100, where E is the en-
zyme activity without the test compounds and S is
the enzyme activity with the test compounds. Inhib-
ition curves were obtained for each compound by plot-
ting the inhibition percentage versus the logarithm of
the inhibitor concentration in the assay solution. Linear
regression parameters were determined for each curve,
and the IC50 values were extrapolated. The same pro-
cedure was applied for the positive control tacrine
(Sigma, purity 98%) and galanthamine (purity >95%)
[12]. The study was approved by the ethical committee in
Kunming Institute of Botany (reference number 1205) and
performed according to the Helsinki Declaration.Conclusion
A series of lycorine derivatives (1–10) were synthesized
and evaluated for anti-cholinesterase activity. The novel
compound 2-O-tert-butyldimethylsilyl-1-O-(methylthio)
methyllycorine (7) was a dual hAChE and hBChE inhibi-
tor. The structure-activity relationships indicated that (i)
Wang et al. Chemistry Central Journal 2012, 6:96 Page 6 of 6
http://journal.chemistrycentral.com/content/6/1/96the 1-O-(methylthio)methyl substituent in lycorine is
better than the 1-O-acetyl group for the inhibition of
cholinesterase; (ii) the acylated or etherified derivatives
of lycorine and lycorin-2-one are more potent against
hBChE than hAChE; and (iii) the oxidation of lycorine at
C-2 decreases the activity. Hence, further study on the
modification of lycorine for the inhibition of ChE is
necessary.
Additional file
Additional file 1: NMR spectra of compounds 1–10.
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